reltecimod (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Organ Dysfunction or Failure

Pending FDA approval for suspected organ dysfunction or failure in patients aged ≥12 years with necrotizing soft tissue infection (NSTI), in conjunction with surgical debridement, antibiotic therapy, and supportive care

Organ Dysfunction or Failure

Pending FDA approval for suspected organ dysfunction or failure in patients aged ≥12 years with necrotizing soft tissue infection (NSTI), in conjunction with surgical debridement, antibiotic therapy, and supportive care

Next:

Pharmacology

Mechanism of Action

Acts early in the host immune response by binding to the dimer interface of CD28 expressed on T-cells, thereby modulating acute inflammation that leads to systemic organ failure

This action avoids ongoing concerns about bacterial resistance and is active independent of the pathogen type

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.